Hidradenitis Suppurativa Study of Izokibep
Public ClinicalTrials.gov record NCT05905783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Study identification
- NCT ID
- NCT05905783
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2023
- Primary completion
- Jul 23, 2024
- Completion
- Jan 26, 2025
- Last update posted
- Oct 14, 2025
2023 – 2025
United States locations
- U.S. sites
- 50
- U.S. states
- 24
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Site | Birmingham | Alabama | 35233 | — |
| Clinical Research Site | Scottsdale | Arizona | 85255 | — |
| Clinical Research Site | Scottsdale | Arizona | 85260 | — |
| Clinical Research Site | Fayetteville | Arkansas | 72703 | — |
| Clinical Research Site | Encino | California | 91436 | — |
| Clinical Research Site | Fountain Valley | California | 92708 | — |
| Clinical Research Site | Fremont | California | 94538 | — |
| Clinical Research Site | Los Angeles | California | 90045 | — |
| Clinical Research Site | Santa Monica | California | 90404 | — |
| Clinical Research Site | Boca Raton | Florida | 33486 | — |
| Clinical Research Site | Brandon | Florida | 33511 | — |
| Clinical Research Site | Coral Gables | Florida | 33134 | — |
| Clinical Research Site | Hollywood | Florida | 33021 | — |
| Clinical Research Site | Tampa | Florida | 33607 | — |
| Clinical Research Site | Tampa | Florida | 33613 | — |
| Clinical Research Site | Atlanta | Georgia | 30315 | — |
| Clinical Research Site | Sandy Springs | Georgia | 30328 | — |
| Clinical Research Site | Savannah | Georgia | 31419 | — |
| Clinical Research Site | Springfield | Illinois | 62702 | — |
| Clinical Research Site | Indianapolis | Indiana | 46250 | — |
| Clinical Research Site | Plainfield | Indiana | 46168 | — |
| Clinical Research Site | Topeka | Kansas | 66614 | — |
| Clinical Research Site | Murray | Kentucky | 42071 | — |
| Clinical Research Site | Baton Rouge | Louisiana | 70808 | — |
| Clinical Research Site | Baton Rouge | Louisiana | 70809 | — |
| Clinical Research Site | New Orleans | Louisiana | 70115 | — |
| Clinical Research Site | Largo | Maryland | 20774 | — |
| Clinical Research Site | Boston | Massachusetts | 02215 | — |
| Clinical Research Site | Canton | Michigan | 48187 | — |
| Clinical Research Site | Troy | Michigan | 48084 | — |
| Clinical Research Site | Lebanon | New Hampshire | 03766 | — |
| Clinical Research Site | New York | New York | 10128 | — |
| Clinical Research Site | Charlotte | North Carolina | 28277 | — |
| Clinical Research Site | Boardman | Ohio | 44512 | — |
| Clinical Research Site | Mason | Ohio | 45040 | — |
| Clinical Research Site | Springfield | Ohio | 45505 | — |
| Clinical Research Site | Portland | Oregon | 97223 | — |
| Clinical Research Site | Hershey | Pennsylvania | 17033 | — |
| Clinical Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Research Site | Sugarloaf | Pennsylvania | 18249 | — |
| Clinical Research Site | Thompson's Station | Tennessee | 37179 | — |
| Clinical Research Site | Arlington | Texas | 76011 | — |
| Clinical Research Site | Frisco | Texas | 75034 | — |
| Clinical Research Site | Pflugerville | Texas | 78660 | — |
| Clinical Research Site | San Antonio | Texas | 78218 | — |
| Clinical Research Site | The Woodlands | Texas | 77380 | — |
| Clinical Research Site | Webster | Texas | 77598 | — |
| Clinical Research Site | Springville | Utah | 84663 | — |
| Clinical Research Site | West Jordan | Utah | 84088 | — |
| Clinical Research Site | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
Recently updated Hidradenitis Suppurativa trials
Other public records listing Hidradenitis Suppurativa. Sorted by last update posted; newest first. Not a recommendation.
- NCT07665437: An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Recruiting
- NCT05507125: Regulation of Inflammatory Genes in Hidradenitis Suppurativa Recruiting
- NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting
- NCT06840392: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting
- NCT06326476: Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. Recruiting
- NCT06799000: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05905783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05905783 live on ClinicalTrials.gov.